Rein Therapeutics, Inc.
About Rein Therapeutics, Inc.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$49.9M
- Total assets
- $24.2M
- Market cap
- $80.7M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $50.6M
- Operating income
- -$50.6M
- Income tax
- -$712.0K
- Net income
- -$49.9M
- EPS (basic)
- $-1.96
- EPS (diluted)
- $-1.96
Balance sheet
- Total assets
- $24.2M
- Current assets
- $4.3M
- Total liabilities
- $7.2M
- Current liabilities
- $6.2M
- Shareholders’ equity
- $16.9M
Cash flow
- Operating cash flow
- -$19.4M
- Investing cash flow
- $9.7M
- Financing cash flow
- $9.8M
- Net cash flow
- $44.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $80.7M
- EPS (diluted)
- $-1.96
- Shares outstanding
- 84.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 29, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $49.9M in FY2025.
- Trading 60% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Rein Therapeutics, Inc..
Write a review
News about Rein Therapeutics, Inc.
News & sentiment via Polygon.io
